Unmet Needs for Treating Myelofibrosis Beyond Symptoms
Raajit Rampal, MD, PhD, discusses unmet needs for therapies to treat patients with myelofibrosis.
Current Status of JAK Inhibition for the Primary Myelofibrosis Population
Raajit Rampal, MD, PhD, discusses the current treatment landscape for patients with myelofibrosis.
Key Considerations for Assessing Risk and Treating Myelofibrosis
Raajit Rampal, MD, PhD, discusses his recommended approach to assessing and treating patients with myelofibrosis.
Challenges in Treating Myelofibrosis
Raajit Rampal, MD, PhD, discusses the challenges and unmet needs of myelofibrosis treatments and highlights promising investigational therapies.
Assessing Treatment Response in Myelofibrosis
Dr Raajit Rampal provides a brief overview of the criteria used to define response to myelofibrosis treatment.
Switching Between Therapies in Myelofibrosis
Dr Raajit Rampal discusses factors to consider when switching between therapies among patients with myelofibrosis.
Pacritinib in Myelofibrosis
Raajit Rampal, MD, PhD, reviews data from the PERSIST trials which support the use of pacritinib for myelofibrosis treatment.
Available Treatment Options for Myelofibrosis
An overview of the currently available treatment options in myelofibrosis.
Myelofibrosis and its Clinical Phenotypes
An explanation of the clinical phenotypes of myelofibrosis.
Myelofibrosis and the COMFORT Trials
Dr Raajit Rampal assesses whether frontline treatment with ruxolitinib was appropriate in the presented patient case with supporting data from the COMFORT-I and -II clinical trials.
Overview: A 67-Year-Old Man with Primary Myelofibrosis
Raajit Rampal, MD, PhD, reviews the case of a 67-year-old man with primary myelofibrosis and shares his initial impressions.
2 Clarke Drive Cranbury, NJ 08512